Business News • PR NewsWire • CStone announces first patient dosed in the global proof-of-concept study of CS1001 in combination with Bayer's regorafenib

CStone announces first patient dosed in the global proof-of-concept study of CS1001 in combination with Bayer's regorafenib

CStone announces first patient dosed in the global proof-of-concept study of CS1001 in combination with Bayer's regorafenib

SUZHOU, China, Jan. 24, 2020 /PRNewswire/ --CStone Pharmaceuticals ("CStone" or the "Company", HKEX: 2616) recently announced that it has dosed the first patient in Australia in a clinical trial of CS1001, an investigational PD-L1 inhibitor developed by CStone, in combination with...

View More : https://www.prnewswire.com:443/news-releases/cstone-announces-first-patient-dosed-in-the-global-proof-of-concept-study-o...

Releted News by prnewswire

Semiconductor Manufacturing Equipment Market Worth USD 119.00 Billion by 2026 at 8.0% CAGR; High Demand for Compact Products to Spur Growth: Fortune Business Insights™

Bank Leumi Raises US$750m Tier 2 Subordinated Notes From International Institutional Investors; A First in the Israeli Financial Sector

Ericsson Reports Fourth Quarter and Full-year Results 2019

CStone announces first patient dosed in the global proof-of-concept study of CS1001 in combination with Bayer's regorafenib

DMCC Announces Crypto Valley in Dubai at Davos 2020, Boosting Blockchain Ecosystem